Loading institutional data...
Loading institutional data...
Held by 170 of 5,944 reporting institutions (90th percentile) — extremely crowded.
Data as of Q1 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading quality & risk...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
Solve the discounted cash flow backwards, then stress-test the assumptions.
To be worth $18.54 today, the market must believe free cash flow compounds 9.9%/yr for a decade (off $42M normalized FCF).
The market's 9.9% is more optimistic than its 9-yr track record.
2-stage DCF · 0.04B shares · net debt $223M
mean -41.5% · volatility σ 59% · implied rate exceeded in 2/7 yrs
Central path = implied 9.9%/yr growth; shaded band = ±1σ (59%) of this company's historical FCF volatility, widening with time. The wider the band, the less certain the growth.
Reverse DCF: rather than guessing a fair value, we solve for the growth the current price implies, then you stress-test the assumptions. Enterprise value of the FCF stream, less net debt, ÷ shares. Educational — not a recommendation.
Total shares institutions bought (green) vs sold (red) each quarter across all holders.
Inferred from quarter-over-quarter change in each fund's 13F position (new stakes count as buys, exits as sells). Not tick-level trades.
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
Ranked against 1085 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-03-31.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BCAX | $1.24T | — | — | — | — | — | — | -34.4% | -34.4% | — | 143 |
| LLY | $1.03T | 50.2× | — | 15.9× | 44.7% | 83.0% | 31.7% | 77.8% | 29.9% | — | 4,193 |
| AKTX | $894.1B | — | — | — | — | — | — | -61.1% | -61.1% | — | 1 |
| JNJ | $650.5B | 24.5× | — | 6.9× | 6.0% | 67.9% | 28.5% | 32.9% | 20.7% | — | 4,451 |
| ABBV | $467.1B | 111.9× | 33.4× | 7.6× | 8.6% | 70.2% | 6.9% | -129% | 6.6% | 4.2× | 3,895 |
| MRK | $368.2B | 20.2× | — | 5.7× | 1.3% | 74.8% | 28.1% | 34.7% | 17.9% | — | 3,594 |
| UNH | $339.9B | 28.4× | 19.7× | 0.8× | 11.8% | 88.7% | 2.7% | 12.0% | 6.8% | 3.9× | 2,891 |
| AZN | $257.7B | — | — | — | — | — | — | — | — | — | 1,248 |
| TMO | $248.2B | 37.1× | 31.9× | 5.6× | 3.9% | — | 15.0% | 12.6% | 7.0% | 4.9× | 2,481 |
| AMGN | $204.6B | 26.7× | 17.6× | 5.6× | 10.0% | 67.2% | 21.0% | 89.1% | 12.2% | 3.8× | 3,014 |
| GILD | $187.3B | 22.3× | 20.4× | 6.4× | 2.4% | 78.8% | 28.9% | 37.5% | 17.9% | 2.4× | 2,218 |
| ABT | $178.0B | 27.5× | 19.2× | 4.0× | 5.7% | 56.4% | 14.7% | 12.5% | 10.0% | 1.4× | 2,964 |
| PFE | $157.1B | 20.3× | — | 2.5× | -1.6% | 74.3% | 12.4% | 9.0% | 5.1% | — | 2,838 |
| DHR | $150.2B | 42.1× | 31.0× | 6.1× | 2.9% | 59.1% | 14.7% | 6.9% | 5.1% | 3.4× | 2,083 |
| ISRG | $136.2B | 48.7× | 37.5× | 13.5× | 20.5% | 66.0% | 28.4% | 16.0% | 16.0% | — | 2,190 |
| VRTX | $131.1B | 33.7× | 28.8× | 10.9× | 8.9% | 86.2% | 32.9% | 21.2% | 21.2% | — | 1,609 |
| BMY | $127.8B | 18.2× | — | 2.6× | -0.2% | 71.1% | 14.6% | 38.2% | 11.1% | — | 2,431 |
| MDT | $118.8B | 24.9× | 12.6× | 3.3× | 8.4% | 65.0% | 13.2% | 9.7% | 9.4% | 0.2× | 2,114 |
| CVS | $114.7B | 64.9× | 11.5× | 0.3× | 7.8% | 45.0% | 0.4% | 2.4% | 2.4% | 0.0× | 1,795 |
| SYK | $107.1B | 33.4× | 18.4× | 4.3× | 11.2% | 64.0% | 12.9% | 14.5% | 8.5% | 2.5× | 2,196 |
| MCK | $102.5B | 22.9× | 16.2× | 0.3× | 12.4% | 3.6% | 1.2% | -219% | 109% | 1.0× | 1,946 |
| HCA | $96.4B | 15.1× | — | 1.3× | 7.1% | — | 9.0% | -113% | 16.8% | — | 1,346 |
| ELV | $91.4B | 16.4× | 15.5× | 0.5× | 12.5% | 89.4% | 2.8% | 12.9% | 7.6% | 4.2× | 1,397 |
| REGN | $82.6B | 19.0× | 19.8× | 5.8× | 1.0% | — | 31.4% | 14.4% | 13.6% | 0.5× | 1,336 |
| CI | $72.7B | 12.4× | 5.5× | 0.3× | 11.2% | 21.8% | 2.2% | 14.3% | 14.1% | 0.0× | 1,583 |
| VREX | $773M | — | — | 0.9× | 4.1% | 34.4% | -8.3% | -14.9% | -8.4% | -79.9× | 170 |
Peers = companies sharing VREX's sector (Healthcare) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.
Top 40 institutional holders — bubble size is position value, color is the move since last quarter. Hover any holder for detail.
Drag any bubble to rearrange · size = dollar value of the position
Is the value real, and is the business safe? Academic scores + earnings quality + solvency, from SEC filings.
Safe > 2.99 · grey 1.81–2.99 · distress < 1.81
Needs granular two-year detail (receivables, PP&E, D&A, SG&A) — not fully reported.
Cash-conversion data unavailable. Lower/negative accruals = higher quality (Sloan).
Interest coverage is thin — monitor; leverage falling year-over-year.
F-Score (0–9 fundamental momentum), Altman Z (distress risk), and Beneish M (earnings-manipulation screen) are academic models computed from the SEC filings. Screens and context — educational, not recommendations.
What the company returns to shareholders — and whether it's covered by cash.
No dividend to cover. Last year: $0 dividends + $0 buybacks = $0 returned on $19M FCF.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How management deployed cash over 10 years — and what it earned on reinvestment.
A reinvestment story — most cash went back into growth rather than to shareholders.
Operating income fell despite reinvestment — a warning on capital productivity. Current ROIC on all capital: -8%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 10 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Cash of $145M covers the $2M due within a year 96.7× over. Scheduled principal only (excludes interest & revolver draws). As of 2025-10-03 (10-K).
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Thin coverage — earnings barely cover interest. Effective rate ~9.7% on $368M of debt.
Cash of $145M fully covers short-term debt of $2M.
Mostly long-term debt (balance-sheet current vs non-current split). See the maturity ladder above for the year-by-year repayment schedule.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Maturity ladder from the SEC long-term-debt repayment schedule. Educational — not a recommendation.
EOD close · as of 2026-09-17
No standout strengths flagged.
Is the profit real, and how strong is the balance sheet?
FY2026 · every deduction from revenue to net income
DuPont — the three levers
Watch the leverage lever — a chunk of ROE comes from the balance sheet.
What the company owes vs. what it holds
Year-by-year maturities aren't in SEC companyfacts (footnote-only), so this shows the debt/cash structure and net leverage instead.
Latest year: profit growth vs revenue growth
Profit and sales moved in opposite directions this year.
Each line as % of revenue — the trend in color
| % of revenue | FY2018 | FY2019 | FY2021 | FY2022 | FY2022 | FY2023 | FY2024 | FY2026 |
|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | 67.2 | 67.1 | 74.2 | 66.8 | 67.0 | 67.5 | 68.3 | 65.6 |
| Gross Profit | 32.8 | 32.9 | 25.8 | 33.2 | 33.0 | 32.5 | 31.7 | 34.4 |
| R&D | 10.7 | 10.0 | 10.7 | 8.8 | 9.0 | 9.5 | 10.7 | 10.8 |
| SG&A | 16.0 | 16.4 | 19.3 | 15.3 | 13.8 | 14.4 | 17.0 | 15.8 |
| Operating Income | 5.8 | 5.9 | -4.6 | 9.1 | 10.3 | 8.6 | 4.0 | -3.3 |
| Income Tax | -0.3 | 0.7 | -2.1 | 1.3 | 1.6 | -1.9 | 6.6 | 1.3 |
| Net Income | 3.6 | 2.0 | -7.8 | 2.1 | 3.5 | 5.3 | -6.0 | -8.3 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on VREX: price, valuation, headline fundamentals, and an auto-generated scorecard from SEC filings. Flags are rule-based signals, not recommendations.
EOD close · as of 2026-09-17
How a revenue dollar becomes profit — FY2026
Each value shows its share of revenue below it (common-size).
| Line Item | FY2026 | FY2024 | FY2023 | FY2022 | FY2022 | FY2021 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $844.6M 100.0% | $811.0M 100.0% | $893.4M 100.0% | $859.4M 100.0% | $818.1M 100.0% | $738.3M 100.0% | $780.6M 100.0% | $773.4M 100.0% | $698.1M 100.0% | $620.1M 100.0% |
| Cost of Revenue | $554.1M 65.6% | $554.1M 68.3% | $603.1M 67.5% | $575.9M 67.0% | $546.6M 66.8% | $548.1M 74.2% | $523.9M 67.1% | $519.5M 67.2% | $444.6M 63.7% | $371.7M 59.9% |
| Gross Profit | $290.5M 34.4% | $256.9M 31.7% | $290.3M 32.5% | $283.5M 33.0% | $271.5M 33.2% | $190.2M 25.8% | $256.7M 32.9% | $253.9M 32.8% | $253.5M 36.3% | $248.4M 40.1% |
| Research & Development | $91.1M 10.8% | $87.0M 10.7% | $84.8M 9.5% | $77.0M 9.0% | $71.9M 8.8% | $78.9M 10.7% | $78.1M 10.0% | $83.0M 10.7% | $67.3M 9.6% | $53.5M 8.6% |
| Selling, General & Admin | $133.3M 15.8% | $137.8M 17.0% | $128.4M 14.4% | $118.3M 13.8% | $125.5M 15.3% | $142.2M 19.3% | $128.1M 16.4% | $123.4M 16.0% | $102.5M 14.7% | $85.8M 13.8% |
| Total Operating Expenses | $318.3M 37.7% | $224.8M 27.7% | $213.2M 23.9% | $195.3M 22.7% | $197.4M 24.1% | $223.9M 30.3% | $211.0M 27.0% | $209.4M 27.1% | $169.8M 24.3% | $139.3M 22.5% |
| Operating Income | -$27.8M -3.3% | $32.1M 4.0% | $77.1M 8.6% | $88.2M 10.3% | $74.1M 9.1% | -$33.7M -4.6% | $45.7M 5.9% | $44.5M 5.8% | $83.7M 12.0% | $109.1M 17.6% |
| Interest Expense | $35.5M 4.2% | $30.2M 3.7% | $29.3M 3.3% | $39.8M 4.6% | $42.1M 5.1% | $31.4M 4.3% | $21.1M 2.7% | $21.7M 2.8% | $12.3M 1.8% | $1.9M 0.3% |
| Interest & Investment Income | $8.5M 1.0% | $7.3M 0.9% | $3.7M 0.4% | $400K 0.0% | $100K 0.0% | $100K 0.0% | $100K 0.0% | $200K 0.0% | $200K 0.0% | $300K 0.0% |
| Other Income (Expense), net | -$31.4M -3.7% | -$27.1M -3.3% | -$45.8M -5.1% | -$43.7M -5.1% | -$45.5M -5.6% | -$38.9M -5.3% | -$24.2M -3.1% | -$18.8M -2.4% | -$8.9M -1.3% | -$4.1M -0.7% |
| Pretax Income | -$59.2M -7.0% | $5.0M 0.6% | $31.3M 3.5% | $44.5M 5.2% | $28.6M 3.5% | -$72.6M -9.8% | $21.5M 2.8% | $25.7M 3.3% | $74.8M 10.7% | $105.0M 16.9% |
| Income Tax Expense | $10.7M 1.3% | $53.3M 6.6% | -$16.6M -1.9% | $13.7M 1.6% | $10.7M 1.3% | -$15.2M -2.1% | $5.7M 0.7% | -$2.6M -0.3% | $22.8M 3.3% | $36.0M 5.8% |
| Net Income | -$70.3M -8.3% | -$48.8M -6.0% | $47.4M 5.3% | $30.3M 3.5% | $17.4M 2.1% | -$57.9M -7.8% | $15.5M 2.0% | $27.5M 3.6% | $51.6M 7.4% | $68.5M 11.0% |
| Per Share | ||||||||||
| EPS (Basic) | $-1.70 | $-1.20 | $1.18 | $0.76 | $0.44 | $-1.49 | $0.41 | $0.73 | $1.37 | $1.83 |
| EPS (Diluted) | $-1.70 | $-1.20 | $1.07 | $0.73 | $0.43 | $-1.49 | $0.40 | $0.72 | $1.36 | $1.82 |
| Weighted Avg Shares (Basic) | 41.4M | 40.8M | 40.3M | 39.8M | 39.3M | 38.8M | 38.2M | 37.9M | 37.6M | 37.4M |
| Weighted Avg Shares (Diluted) | 41.4M | 40.8M | 50.3M | 41.6M | 40.3M | 38.8M | 38.6M | 38.4M | 38.0M | 37.7M |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.